This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Branded by AVITA Medical and co-developed with Regenity Biosciences, Cohealyx may reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds. AVITA Medical plans to develop clinical data for Cohealyx in early 2025 to build on the preclinical success and support the products commercial launch.
Estheticians and consumers alike understand the advanced changes that can be made within a medical setting - and physicians are realizing the supportive role that Estheticians can bring to their practices. Working in a medical setting as an Esthetician can be both rewarding and beneficial for both yourself and your clients alike.
Our Online Laser Training International Programme Director, Dr Godfrey Town has been re-certified from 1st May 2023 by RPA 2000 for a further five years to act as a Laser Protection Adviser (LPA) and Dr Town holds this for medical, research and teaching.
Alexis (Lexi) Stern is Merz Aesthetics’ new Chief Marketing Officer. Stern will join the global leadership team and will be responsible for leading the portfolio and brand strategies. Stern will report directly to Bob Rhatigan, Chief Executive Officer, Merz Aesthetics. Most recently, Ms.
Unfortunately, a steep road awaits nurses who exit the medical field entirely. If you’re still passionate and ambitious when it comes to working in the medical field, consider pivoting to a different sector of health care: aesthetic medicine! Practitioners are free and encouraged to exercise their best medical judgment.
We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” says Hervé Hoppenot, Chief Executive Officer, Incyte, in a news release.
Brett Fair Named National Sales Director at Sun Pharma Brett Fair is now Sun Pharma’s National Sales Director for the medical dermatology sales team. In this role, Mr. Fair is responsible for the promotion of Winlevi and Absorica LD. Before joining Sun Pharma, he served as Vice President of Corporate Development at Novan Therapeutics.
“We are encouraged by the outcome from the recent FDA meeting and the opportunity to advance our development of prabotulinumtoxinA utilizing the 351(k) biosimilar regulatory pathway,” says Marc Forth, AEON’s President and Chief Executive Officer, in a news release. “We
However, medications that are already authorized are just a small percentage of what's been studied. Many researchers are still trying to find and develop other medications that can treat or prevent COVID-19. It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement.
and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.
and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.
The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.
This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.
We are thrilled to announce this agreement with Kaken, a dermatology leader with significant reach and expertise in the Japanese market, says Martin Babler, President and Chief Executive Officer of Alumis, in a news release. ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content